MX2019014427A - Forma cristalina de n-butildeoxigalactonojirimicina. - Google Patents

Forma cristalina de n-butildeoxigalactonojirimicina.

Info

Publication number
MX2019014427A
MX2019014427A MX2019014427A MX2019014427A MX2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A
Authority
MX
Mexico
Prior art keywords
crystalline form
butyldeoxygalactonojirimycin
triol
piperidine
hydroxymethyl
Prior art date
Application number
MX2019014427A
Other languages
English (en)
Inventor
Oliveira Vitor
Pogorelic Ivan
Paul RODUIT Jean-
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2019014427A publication Critical patent/MX2019014427A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a una forma cristalina de [(2R, 3S, 4R, 5S)-1-butil-2-(hidroximetil)-piperidina-3,4,5-triol, procesos para la preparación de la misma, composiciones farmacéuticas que contienen dicha forma cristalina, y su uso como medicamento, especialmente como inhibidor de la biosíntesis de glucolípidos.
MX2019014427A 2017-06-01 2018-05-31 Forma cristalina de n-butildeoxigalactonojirimicina. MX2019014427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017063287 2017-06-01
PCT/EP2018/064365 WO2018220131A1 (en) 2017-06-01 2018-05-31 Crystalline form of n-butyldeoxygalactonojirimycin

Publications (1)

Publication Number Publication Date
MX2019014427A true MX2019014427A (es) 2020-02-05

Family

ID=62492649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014427A MX2019014427A (es) 2017-06-01 2018-05-31 Forma cristalina de n-butildeoxigalactonojirimicina.

Country Status (18)

Country Link
US (2) US11306058B2 (es)
EP (1) EP3630725A1 (es)
JP (2) JP6937850B2 (es)
KR (1) KR102612650B1 (es)
CN (1) CN110799497A (es)
AU (1) AU2018278247B2 (es)
BR (1) BR112019025125A2 (es)
CA (1) CA3065147A1 (es)
CL (1) CL2019003478A1 (es)
EA (1) EA201992807A1 (es)
IL (1) IL270961A (es)
MA (1) MA48944A (es)
MX (1) MX2019014427A (es)
MY (1) MY201196A (es)
PH (1) PH12019502635A1 (es)
TW (1) TWI770184B (es)
UA (1) UA125938C2 (es)
WO (1) WO2018220131A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065147A1 (en) * 2017-06-01 2018-12-06 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin
US20220411371A1 (en) 2019-09-25 2022-12-29 Teva Pharmaceuticals International Gmbh Solid state forms of lucerastat and process for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2006037069A1 (en) 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
KR20080033463A (ko) 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
JP2009538276A (ja) 2006-04-24 2009-11-05 アカデミッシュ メディシュ セントラム 嚢胞性線維症の改良型治療
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
ITMI20122090A1 (it) 2012-12-06 2014-06-07 Dipharma Francis Srl Sintesi di un inibitore delle glicosiltransferasi
CA3065147A1 (en) * 2017-06-01 2018-12-06 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin

Also Published As

Publication number Publication date
IL270961A (en) 2020-01-30
CA3065147A1 (en) 2018-12-06
TW201902876A (zh) 2019-01-16
BR112019025125A2 (pt) 2020-07-21
WO2018220131A1 (en) 2018-12-06
JP6937850B2 (ja) 2021-09-22
US20200140385A1 (en) 2020-05-07
MA48944A (fr) 2020-04-08
UA125938C2 (uk) 2022-07-13
EP3630725A1 (en) 2020-04-08
KR102612650B1 (ko) 2023-12-11
MY201196A (en) 2024-02-09
JP7373529B2 (ja) 2023-11-02
US11306058B2 (en) 2022-04-19
CL2019003478A1 (es) 2020-06-05
AU2018278247B2 (en) 2022-07-28
TWI770184B (zh) 2022-07-11
JP2021185184A (ja) 2021-12-09
US20220002245A1 (en) 2022-01-06
EA201992807A1 (ru) 2020-05-20
PH12019502635A1 (en) 2020-07-13
US11713297B2 (en) 2023-08-01
AU2018278247A1 (en) 2020-01-16
KR20200011992A (ko) 2020-02-04
JP2020521796A (ja) 2020-07-27
CN110799497A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
PH12018500425A1 (en) Novel 6-6 bicyclic aromatic ring substituted nuceloside analogues for use as prmt5 inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
WO2015160843A8 (en) Ion channel activators and methods of use
MX2020005944A (es) Analogos espirobiciclicos novedosos.
MX2017014035A (es) Formas solidas novedosas.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12018500377A1 (en) Novel annelated benzamides
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
PH12018500378A1 (en) Novel annelated phenoxyacetamides
EP4066835A4 (en) USE OF A COMPOSITION FOR INCREASE ANTI-CANCER EFFECT HAVING A GAMMA INHIBITOR AS THE ACTIVE INGREDIENT
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
SG11201907472QA (en) Composition for inhibiting myofibrosis
PH12019502635A1 (en) Crystalline form of n-butyldeoxygalactonojirimycin
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
AU2018246257A8 (en) Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
EP3733212A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER METASTASIS IN THE LUNG WITH CHI3L1 INHIBITOR AS THE ACTIVE SUBSTANCE
MX2012002580A (es) Compuesto antibacteriano novedoso de hidroxifenilo.
WO2017064635A3 (en) Saroglitazar magnesium, compositions containing it, process for its preparation
EP4180048A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A CER COMPOUND AS ACTIVE INGREDIENT
PH12018501895A1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors
TR201722304A2 (tr) Oseltami̇vi̇r fosfatin farmasöti̇k kapsül kompozi̇syonlari
EP3750882A4 (en) DIACYLGLYCERIN-LACTONE COMPOUND, PROCESS FOR THEIR PRODUCTION AND THIS IMMUNSTIMULATOR CONTAINING THE ACTIVE SUBSTANCE